CollPlant Biotechnologies | Pioneering Regenerative Medicine

Our Mission

Pioneering collagen-based technologies and regenerative medicine products to improve and prolong lives

Company Overview

CollPlant Biotechnologies (Nasdaq: CLGN) is a regenerative and aesthetic medicine company focused on tissue regeneration and 3D bioprinting of tissues and organs.

The Company's products are based on rhCollagen (recombinant human collagen), its proprietary plant-based genetic engineering technology platform, that enables mass production of true Type I human collagen.

CollPlant's products address tissue repair and aesthetics indications, and the Company is ushering in a new era in regenerative and aesthetic medicine.

CollPlant has an agreement worth up to $103 million, plus royalties, for dermal and soft tissue fillers with AbbVie (NYSE:ABBV), the global leader in the $5.5 billion dermal filler market.

CollPlant is developing 3D bioprinted breast implants for regeneration of breast tissue, a $2.6 billion market, and is actively pursuing additional business development collaborations with top-tier companies for use of its rhCollagen in the production of unlimited and economical manufactured organs.

Equity Overview (as of 10.25.2023)

NASDAQ: **CLGN**	Stock Price: **$5.28**	Market Cap: **$60 M**	Avg. Trading Volume (shares): **~16,000**	Shares Outstanding: **~11.4 M**	Cash on Hand (6/30/23): **$22 M***

*In addition, CollPlant received in July 2023 $10 M from AbbVie, for the achievement of a milestone

Strategic Agreements with

AbbVie
(NYSE:ABBV)

Stratasys
(Nasdaq: SSYS)

Disclaimer: Except for historical information contained herein, the statements in this fact sheet are "forward looking" within the meaning of the Private Securities Litigation Act of 1995. This fact sheet includes estimates and projections and, as such, reflects only management's current expectations. A fuller discussion of CollPlant Biotechnologies Ltd.'s risks and uncertainties are described in the Company's filings with the Securities and Exchange Commission, which should be reviewed in conjunction with this overview.

Aesthetic Medicine
Dermal Fillers

Regenerative Medicine
3D Bioprinting | Breast implants

Gut-on-a-Chip

Our Proprietary Technology: The Only Commercially Viable Production of True Human Collagen

Collagen is an essential building block of the human body, providing structural support and biological signals to connective tissues and organs. It is a crucial component of tissue regeneration. CollPlant has the only commercially viable technology currently available to mass-produce true Type I recombinant human collagen.

Our technology introduces five human genes essential to the synthesis of Type I collagen into tobacco plants.

These transgenic tobacco plants produce human collagen superior to collagen currently on the market that is sourced from animals and human cadavers.

This is because our rhCollagen is identical to natural human collagen and does not elicit an adverse immune response. Its plant origin yields a product with greater purity and more consistent properties, making it the ideal building block for regenerative medicine.

Plant-derived

Animal Extracted

☐ = cell binding domains

Programs Based on CollPlant's Non-Animal rhCollagen Derived from Plants
Regenerative Dermal Fillers (in development with AbbVie in a $5.5 B Market)

CollPlant has a development and commercialization agreement with AbbVie, for CollPlant's rhCollagen to be used in dermal and soft tissue filler products, that is in clinical phase. In an agreement, CollPlant has received $14 million upfront, and in June 2023 announced the achievement of a milestone which triggers a $10 million immediate payment from AbbVie. CollPlant is entitled to an additional $79 million in milestone and option payments, plus royalty payments on future product sales and fees

for the manufacture and supply of rhCollagen to AbbVie. Combining rhCollagen's superior properties with AbbVie's propriety technologies, this collaboration is expected to create a paradigm shift in the medical aesthetic field by providing next-generation regenerative products with long lasting results.CollPlant is also developing injectable breast implants and a photocurable dermal filler, to which AbbVie has rights of first negotiation for worldwide exclusive licenses.

3D Bioprinted Regenerative Breast Implants for $2.6 B Market

CollPlant is developing a regenerative 3D bioprinted breast implants aimed at providing a revolutionary alternative to current implants – both reconstructive and aesthetic - which are associated with a high risk of adverse events. According to the FDA, patients with breast implants have an increased risk of developing breast implant Associated-Anaplastic Large Cell Lymphoma. These regenerative breast implants are designed to gradually degrade and be replaced by newly grown natural breast tissue.

In January 2023 CollPlant completed a large animal study, with full achievement of study objectives, demonstrating tissue regeneration which included the formation of maturing connective tissue and neovascular networks, as the implant gradually biodegrades. The results of this study provide the basis for the design of a large-animal pivotal study planned for this year. The Company expects that these animal studies will support the advancement of the product candidate into human clinical trials.

Gut-on-a-Chip model for Inflamatory Bowel Disease (IBD)

Our gut-on-a-chip model is designed to accurately mimic the human intestine tissue structure and function. Chip technologies offer significant potential to change the diagnostic paradigm and personalized treatment landscape with both refined and cost-effective laboratory testing.

Patient-specific cells enable screening of multiple drugs and identification of the most effective personalized therapeutic response. In addition to better mimicking the effects on human tissue, they also offer the potential to avoid animal testing for ethical reasons. Our first application of this technology is in ulcerative colitis disease – a form of inflammatory bowel disease, or IBD.

IBD is characterized by chronic inflammation, a relapsing and remitting clinical course and life-long treatment. There is a need for novel personalized platforms to improve therapeutic choices and patient outcome for these conditions.

Collink.3D™ BioInks for Tissue and Organ Manufacturing

Collink.3D™ is the first and only human collagen bioink platform, based on non-animal-derived recombinant human Type I collagen (rhCollagen), allowing for perfect mimicry of the properties of human native tissue or organs. It enables the scalable and reproducible bio-fabrication of scaffolds, tissues, and organs for 3D modeling and transplantation. Bio-fabricated constructs using Collink.3D offer superior biological performance, consistency, and safety, and can be used in applications including drug discovery, drug screening, and tissue testing, as well as development and manufacture of transplantable tissues, scaffolds, and organs.

Collink.3D is compatible with major 3D bioprinting technologies and cell types. CollPlant and Stratasys, a leader in additive manufacturing with decades of 3D printing experience, have a joint development and commercialization agreement to collaborate on the development of a solution to bio-fabricate human tissues and organs. The first project focuses on the development of an industrial-scale solution to produce CollPlant's regenerative, first-ever breast implant based on its rhCollagen technology using Stratasys' new bioprinter based on its precise P3™ 3D printing technology with CollPlant's rhCollagen-based bioinks.

CollPlant
Biotechnologies | Pioneering Regenerative Medicine